Oncolytics Biotech (TSE:ONC) Shares Down 9.3% – Time to Sell?

Oncolytics Biotech Inc. (TSE:ONC)’s stock price fell 9.3% during trading on Friday . The stock traded as low as C$0.98 and last traded at C$0.98. 103,958 shares were traded during mid-day trading, a decline of 15% from the average session volume of 123,015 shares. The stock had previously closed at C$1.08.

Analysts Set New Price Targets

Separately, Raymond James upgraded shares of Oncolytics Biotech to a “moderate buy” rating in a research report on Thursday, November 14th.

Oncolytics Biotech Stock Down 8.3 %

The stock has a market capitalization of C$76.30 million, a P/E ratio of -2.76 and a beta of 1.35. The company has a debt-to-equity ratio of 11.75, a current ratio of 2.99 and a quick ratio of 8.86. The firm has a 50-day simple moving average of C$1.14 and a 200 day simple moving average of C$1.31.

About Oncolytics Biotech

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.